Close search filters
Changing filters will change the listed Success Criteria and Techniques
Category
Topic
Search results (25)
Article
Leveraging biosimilars to drive savings and support patient access
By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.
Read MoreArticle
Boosting Biosimilars Competition and Savings
September 25, 2023
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Article
Why a home infusion strategy is more important than ever
Growing demand and new regulations have put the onus on plan sponsors to prioritize the need for a comprehensive home infusion strategy.
Read MoreArticle
Meet Eric Palmer, president and chief executive officer of Evernorth Health Services
April 26, 2023
Eric Palmer's career journey started with a summer internship at Cigna Healthcare. Today, he leads Evernorth Health Services, supporting employers and health plans in improving the health of their mem...
Article
Gene therapies: Million-dollar miracles
August 31, 2023
Gene therapies bring much-needed hope for treating rare conditions, but also concerns, especially around affordability. Learn about strategies plan sponsors can take to address these million-dollar me...